I saw it. Check this out...”In Brilacidin oral rinse, we now have a Phase 3-ready drug candidate targeting an area of large unmet need—comprising a worldwide annual market opportunity estimated to approach $1 billion—for which currently there are no FDA-approved treatments.”
The death of Prurisol was already baked into the Innovation share price. Some will try to make more of that but I don’t see that as anything but slightly disappointing considering the go-ahead from the FDA on Phase 3 B-OM.
News 
Market Data 
Discover 
